Caladrius Biosciences (CLBS) Reports Q3 Loss Per Share of $1.33

Caladrius Biosciences (NASDAQ: CLBS) reported Q2 EPS of ($1.33), may not compare to the analyst estimate of ($1.75). Revenue for the quarter came in at $8.3 million versus the consensus estimate of $7.53 million.

2016 Financial Guidance

The Company reaffirms its previous guidance as follows:

• Consolidated Revenues: to exceed $30 million or a greater than 30% increase compared with 2015
• Capital Improvements at PCT’s Allendale, NJ facility: ~$6 million, to be completed by end of first half of 2017
• CLBS03 Phase 2 Study Costs in 2016: $6 million to $7 million
• Consolidated Annual Operating Cash Burn: $25 million to $28 million in 2016, with lower operating cash burn in the second half of 2016 than in the first half of the year

For earnings history and earnings-related data on Caladrius Biosciences (CLBS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c